Ribocure Pharmaceuticals AB, Overseas R&D Center of siRNA Leader Ribo Life Science, Secures $33 Million Equity Financing

This round of financing was led by the renowned Swedish investor Erik Serrin（Erik Selin）Mr. [Name] Leads Investment, GoCo Science Park in Gothenburg, Sweden（GoCo Health Innovation City）CEO Jacob Triell（Jacob Torell）PhD Follow-up Investment.After the financing was completed, Mr. Salin joined the board of directors of Ribo Life Science.。

Ribo Life Science is focused on small nucleic acids（siRNA）A global leader in drug research and development, aligned with the innovative forefront of international small nucleic acid technology, committed to the iterative R&D of small nucleic acid chemical modifications and drug delivery technologies. It has established an autonomous and fully integrated small nucleic acid drug R&D platform, supporting all stages of small nucleic acid drug research from early development to industrialization.

Ribo Life ScienceAroundCardiovascular, Metabolic, Hepatic, Renal, and Other Therapeutic AreasHas established a rich product pipeline, among which the self-developed liver-targeting RiboGalSTARTM delivery technology has advanced multiple products.Phase II Clinical Stage, with efficacy and safety well clinically validated.

At the same time,Ribo Life ScienceAdhere to differentiated target and product layout, possess an international innovative R&D team, conduct product R&D and commercialization globally, and strive to bring new drug treatment options to patients as soon as possible.